ReviewExpert opinion on drug delivery2021
Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications.
Review in Expert opinion on drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Therapeutic embolic agents for targeted drug delivery in transcatheter therapies: a review.Chemical communications (Cambridge, England) · 2026Review
- Article
- Review
- Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.Clinical Medicine Insights. Oncology · 2026Article
- Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study.Frontiers in oncology · 2026Article
- Hydrogel Microspheres for Biomedical Applications.Small science · 2026Review
- Emerging Techniques and Treatment Outcomes in Pulmonary Arteriovenous Malformations Embolisation: A Narrative Review.Journal of clinical medicine · 2025Review
- Embolic efficacy and safety profile of UniPearlsJournal of materials science. Materials in medicine · 2025Article
- A multi-modal embolic gel system for long-term fluorescence imaging and photothermal therapy.Biomaterials advances · 2025Article
- Tumor vessel-adaptable adhesive and absorbable microspheres for sustainable transarterial chemoembolization therapy.Nature communications · 2025Article
- Sorafenib-Drug Delivery Strategies in Primary Liver Cancer.Journal of functional biomaterials · 2025Review
- Advanced targeted microsphere embolization for arteriovenous malformations: state-of-the-art and future directions.Neuroradiology · 2025Review
- Superselective embolic particle guidance in vessel networks via shape-adaptive acoustic manipulation.Nature communications · 2025Article
- Personalized peripheral vascular interventional embolization for tumor: tailoring treatment to improve outcomes.Frontiers in medicine · 2025Review
- Microbubbles bound to drug-eluting beads enable ultrasound imaging and enhanced delivery of therapeutics.Scientific reports · 2024Article
- Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.Abdominal radiology (New York) · 2024Article
- Clinical research progress of callisperesDiscover oncology · 2024Review
- Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma.Materials today. Bio · 2024Article
- Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionDrug-eluting embolic (DEE) microspheres, or drug-eluting beads (DEB), delivered by transarterial chemoembolization (TACE) serve as a therapeutic embolic to stop blood flow to tumors and a drug delivery vehicle. New combinations of drugs and DEE microspheres may exploit the potential synergy between mechanisms of drug activity and local tissue responses generated by TACE to enhance the efficacy of this mainstay therapy. AREAS COVERED: This review provides an overview of key drug delivery concepts related to DEE microspheres with a focus on recent technological developments and promising emerging clinical applications as well as speculation into the future. EXPERT OPINION: TACE has been performed for nearly four decades by injecting chemotherapy drugs into the arterial supply of tumors while simultaneously cutting off their blood supply, trying to starve and kill cancer cells, with varying degrees of success. The practice has evolved over the decades but has yet to fulfill the promise of truly personalized therapies envisioned through rational selection of drugs and real-time multi-parametric image guidance to target tumor clonality or heterogeneity. Recent technologic and pharmacologic developments have opened the door for potentially groundbreaking advances in how TACE with DEE microspheres is performed with the goal of achieving advancements that benefit patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.